Nimble Therapeutics announced that the company has expanded its collaboration and executed a license agreement with Genentech, a member of the Roche Group, for the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas. Under the terms of the agreement, Nimble will receive a $20M upfront payment; near-term, preclinical, clinical, and commercial milestone payments that could exceed $1.1B; as well as tiered royalties. Nimble will apply its platform against multiple targets, and Genentech and Roche will be responsible for preclinical and clinical development, and commercialization of any resulting products. "We are excited to significantly expand our partnership and strengthen our collaboration with Genentech. Genentech has been a valuable strategic partner and we are proud that our success thus far has led to the opportunity to significantly broaden our work together with both Genentech and Roche," said Jigar Patel, Founder and CEO of Nimble Therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RHHBY:
- FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
- Roche downgraded on ‘tougher 2023 catalyst path’ at Jefferies
- Roche downgraded to Hold from Buy at Jefferies
- Roche downgraded to Underweight from Neutral at JPMorgan
- FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma